Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ezekowitz

Showing results (541-550 of 842) with videos related to

Pageof 85
Sort By:
European Heart Journal|April 19, 2013
Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trialSana M Al-Khatib, Laine Thomas, Lars Wallentin, et al.
Lancet (London, England)|August 31, 2010
Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trialLars Wallentin, Salim Yusuf, Michael D Ezekowitz, et al.
European Journal of Heart Failure|September 1, 2023
Relationship between baseline electrocardiographic measurements and outcomes in patients with high-risk heart failure: Insights from the VerICiguaT Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) trialHaran Yogasundaram, Yinggan Zheng, Eric Ly, et al.
International Journal of Clinical Practice|January 15, 2021
Non-vitamin K antagonist oral anticoagulant (NOAC) use and dosing in Canadian practice: Insights from the optimising pharmacotherapy in the management approach to lowering risk in atrial fibrillation (OPTIMAL AF) ProgrammeKori Leblanc, Alan D Bell, Justin A Ezekowitz, et al.
The Canadian Journal of Cardiology|September 25, 2017
Heart Failure in Young Adults Is Associated With High Mortality: A Contemporary Population-Level AnalysisChih M Wong, Nathaniel M Hawkins, Justin A Ezekowitz, et al.
Journal of the American Heart Association|December 3, 2015
Providing Rapid Out of Hospital Acute Cardiovascular Treatment 4 (PROACT-4)Justin A Ezekowitz, Robert C Welsh, Dale Weiss, et al.
Journal of the American Heart Association|December 9, 2020
Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial FibrillationZiad Hijazi, Lars Wallentin, Johan Lindbäck, et al.
Cardiovascular Research|August 6, 2021
Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillationTymon Pol, Ziad Hijazi, Johan Lindbäck, et al.
Journal of the American Heart Association|June 2, 2020
Comparative Effectiveness of Primary Prevention Implantable Cardioverter-Defibrillators in Older Heart Failure Patients With Diabetes MellitusAbhinav Sharma, Jingjing Wu, Haolin Xu, et al.
Lancet (London, England)|December 10, 2013
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trialsChristian T Ruff, Robert P Giugliano, Eugene Braunwald, et al.
Pageof 85

Showing results (541-550 of 842) with videos related to

Sort By:
Pageof 85
European Heart Journal|April 19, 2013
Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trialSana M Al-Khatib, Laine Thomas, Lars Wallentin, et al.
Lancet (London, England)|August 31, 2010
Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trialLars Wallentin, Salim Yusuf, Michael D Ezekowitz, et al.
European Journal of Heart Failure|September 1, 2023
Relationship between baseline electrocardiographic measurements and outcomes in patients with high-risk heart failure: Insights from the VerICiguaT Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) trialHaran Yogasundaram, Yinggan Zheng, Eric Ly, et al.
International Journal of Clinical Practice|January 15, 2021
Non-vitamin K antagonist oral anticoagulant (NOAC) use and dosing in Canadian practice: Insights from the optimising pharmacotherapy in the management approach to lowering risk in atrial fibrillation (OPTIMAL AF) ProgrammeKori Leblanc, Alan D Bell, Justin A Ezekowitz, et al.
The Canadian Journal of Cardiology|September 25, 2017
Heart Failure in Young Adults Is Associated With High Mortality: A Contemporary Population-Level AnalysisChih M Wong, Nathaniel M Hawkins, Justin A Ezekowitz, et al.
Journal of the American Heart Association|December 3, 2015
Providing Rapid Out of Hospital Acute Cardiovascular Treatment 4 (PROACT-4)Justin A Ezekowitz, Robert C Welsh, Dale Weiss, et al.
Journal of the American Heart Association|December 9, 2020
Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial FibrillationZiad Hijazi, Lars Wallentin, Johan Lindbäck, et al.
Cardiovascular Research|August 6, 2021
Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillationTymon Pol, Ziad Hijazi, Johan Lindbäck, et al.
Journal of the American Heart Association|June 2, 2020
Comparative Effectiveness of Primary Prevention Implantable Cardioverter-Defibrillators in Older Heart Failure Patients With Diabetes MellitusAbhinav Sharma, Jingjing Wu, Haolin Xu, et al.
Lancet (London, England)|December 10, 2013
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trialsChristian T Ruff, Robert P Giugliano, Eugene Braunwald, et al.
Pageof 85